What a tirzepatide COA cannot verify

A certificate of analysis, often shortened to COA, may look reassuring when someone is offering powdered tirzepatide. It is not, by itself, proof that a product is an FDA-approved medicine, that it came from a licensed pharmacy, or that it is appropriate for a particular person. The FDA says unapproved versions of GLP-1 medicines do not go through its review for safety, effectiveness, and quality before marketing^[1]. A document from a seller does not replace those safeguards.

The useful question is not whether a COA exists. It is what the document can establish about a stated sample, and what remains outside its reach. This explainer does not assess vendors, authenticate reports, or explain how to prepare injectable products. If someone is considering tirzepatide, the safer route is a prescription and dispensing through a licensed pharmacy. The FDA specifically advises patients using compounded GLP-1 drugs to obtain a prescription from their doctor and fill it at a state-licensed pharmacy^[1].

What a COA is, in the narrow sense

A COA is a report that purports to describe testing on a sample. Depending on what the report actually says, it may identify a named analyte or list measured characteristics. That is narrower than a guarantee about every vial in circulation. A report is only as informative as its connection to the item in question, the sample tested, and the testing described. It also does not turn an unapproved product into an approved medicine.

That distinction matters because FDA approval is a separate regulatory process. FDA explains that compounded drugs are not FDA-approved, meaning the agency does not verify their safety, effectiveness, or quality before they are marketed^[2]. FDA also distinguishes a compounded drug from an approved generic drug. A COA cannot settle either of those regulatory questions.

What a COA cannot establish

A COA cannot establish that a seller is licensed, that a product was legally supplied for human use, or that its label and instructions are accurate. It cannot substitute for a clinician's assessment of whether tirzepatide is appropriate, whether it may interact with other medicines, or whether a reported symptom needs care. Those are different questions from a laboratory report's stated result.

It also cannot by itself provide the FDA review that applies to an approved prescription product. FDA says compounded drugs should only be used when a patient's medical needs cannot be met by an FDA-approved drug^[1]. The agency's guidance is not a claim that every compounded preparation is unsafe. It explains that compounding sits outside the approval pathway and has a limited role.

For products represented as brand-name medicines, a report cannot rule out counterfeiting. FDA notes that counterfeit drugs can contain the wrong ingredients, too little, too much, no active ingredient, or other harmful ingredients^[1]. That is why a single document should not be treated as an end-to-end verification system for a product acquired outside normal pharmacy dispensing.

Why homemade injection questions need a different answer

The community question behind this article involves powder and bacteriostatic water. That moves beyond reading a document into preparing an injectable medicine outside the labelled product format. The FDA has reported adverse events that may be related to patients receiving compounded semaglutide or tirzepatide in doses beyond the approved label, while noting that it cannot determine from reports alone whether the drug directly caused an event^[1]. That uncertainty is a reason not to turn a forum answer into a preparation guide.

The approved US product has its own prescribing information and instructions. DailyMed publishes the current Zepbound label as drug-labelling information^[3]. A loose powder plus a liquid supplied by an informal contact is not the same presentation, even if someone calls the material tirzepatide. A clinician or pharmacist can help a patient compare a prescription product, its label, and its dispensing record with what they have been offered.

Questions worth taking to a clinician or pharmacist

Rather than asking an informal seller how to use a product, bring the situation to a licensed clinician or pharmacist. They can address whether there is a valid prescription, whether the product was dispensed through a licensed pharmacy, and whether the proposed use matches an approved label or a legitimate compounded prescription. They can also advise on urgent symptoms, other medicines, and medical history. A forum cannot do that safely.

For background on the medicine itself, see our tirzepatide overview and the US regulatory overview. These pages explain the distinction between an authorised prescription medicine and products marketed outside that system. They are educational resources, not a substitute for care.

What we do not yet know

A report shared in a private transaction does not provide enough information to establish the identity, quality, handling, or clinical suitability of the item a reader may receive. We cannot authenticate an individual COA or infer safety from it. We also cannot determine whether a particular product is compounded lawfully or whether it meets a person's medical needs. Those limits are the point: evidence about a document is not the same as evidence about a medicine in a patient's hands.

A COA does not replace the medicine pathway

A COA may describe testing claimed for a sample, but it cannot replace FDA approval, pharmacy dispensing, a valid prescription, or individual clinical assessment. FDA's current advice on unapproved GLP-1 products is to use a prescription from a doctor and a state-licensed pharmacy^[1]. If the decision involves a powder, an informal supplier, or any plan to prepare an injection, pause and speak with a clinician or pharmacist rather than relying on a seller's document or a social-media thread.